How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04.

What other stocks do shareholders of Clementia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clementia Pharmaceuticals investors own include Global Blood Therapeutics (GBT) , Madrigal Pharmaceuticals (MDGL) , JPMorgan Chase & Co. (JPM) , Exelixis (EXEL) , EyePoint Pharmaceuticals (EYPT) , MyoKardia (MYOK) , Rigel Pharmaceuticals (RIGL) , Endocyte (ECYT) , Amicus Therapeutics (FOLD) and Incyte (INCY) .

When did Clementia Pharmaceuticals IPO?

Clementia Pharmaceuticals (CMTA) raised $101 million in an IPO on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

NASDAQ:CMTA

Clementia Pharmaceuticals (CMTA) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free CMTA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $26.28
▼
$26.69
50-Day Range: $26.35
▼
$26.35
52-Week Range: $8.10
▼
$26.73

Volume: 716,706 shs
Average Volume: 145,059 shs
Market Capitalization: $1.00 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Clementia Pharmaceuticals alerts:

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Clementia Pharmaceuticals Stock (NASDAQ:CMTA)

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

CMTA Stock News Headlines

January 6, 2022 | investing.com

Clementia Pharmaceuticals Inc (CMTA)

See More Headlines

Receive CMTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clementia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CMTA
CUSIP: N/A
CIK: 1647320
Web: www.clementiapharma.com
Phone: 514-940-3600
Fax: N/A
Employees: 30
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -44.73%
Return on Assets: -41.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.03
Quick Ratio: 14.03

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.18 per share
Price / Book: 5.09

Miscellaneous

Outstanding Shares: 38,060,000
Free Float: N/A
Market Cap: $1.00 billion
Optionable: Not Optionable
Beta: 0.64

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Clarissa Desjardins (Age 52)
Founder, Pres, CEO & Director
Dr. Donna Roy Grogan M.D. (Age 62)
Chief Medical Officer
Mr. Jeffrey Packman (Age 52)
Chief Devel. Officer
Mr. Steve Forte (Age 40)
CFO & Corp. Sec.
Mr. Joseph Andrew Walewicz (Age 50)
Exec. VP of Bus. & Corp. Devel.

Key Competitors

View All Competitors

CMTA Stock Analysis - Frequently Asked Questions

How were Clementia Pharmaceuticals' earnings last quarter?: Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04.
What other stocks do shareholders of Clementia Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Clementia Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Madrigal Pharmaceuticals (MDGL), JPMorgan Chase & Co. (JPM), Exelixis (EXEL), EyePoint Pharmaceuticals (EYPT), MyoKardia (MYOK), Rigel Pharmaceuticals (RIGL), Endocyte (ECYT), Amicus Therapeutics (FOLD) and Incyte (INCY).
When did Clementia Pharmaceuticals IPO?: Clementia Pharmaceuticals (CMTA) raised $101 million in an IPO on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

This page (NASDAQ:CMTA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Clementia Pharmaceuticals (CMTA) Stock Price, News & Analysis

About Clementia Pharmaceuticals Stock (NASDAQ:CMTA)

CMTA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CMTA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info